Duration of Antibiotic Treatment for Foot Osteomyelitis in People with Diabetes

Publication date

2024-12

Authors

Gramberg, Meryl Cinzía Tila Tamara
Torensma, Bart
van Asten, Suzanne
Sieswerda, ElskeORCID 0000-0001-5819-4918
Sabelis, Louise Willy Elizabeth
den Heijer, Martin
de Vries, Ralph
de Groot, Vincent
Peters, Edgar Josephus Gerardus

Editors

Advisors

Supervisors

Document Type

Article

Collections

Open Access logo

License

cc_by

Abstract

Background: The optimal antimicrobial treatment duration for diabetes-related foot osteomyelitis (DFO) currently needs to be determined. We systematically reviewed the effects of short and long treatment durations on outcomes of DFO. Methods: We performed a systematic review searching Cochrane, CENTRAL, MEDLINE, Embase, and CINAHL Plus from inception up to 19 January 2024. Two independent reviewers screened the titles and abstracts of the studies. Studies comparing short (<6 weeks) and long (>6 weeks) treatment durations for DFO were included. The primary outcome was amputation; the secondary outcomes were remission, mortality, costs, quality of life, and adverse events. Risk of bias and GRADE were assessed. Results: We identified 2708 references, of which 2173 remained after removing duplicates. Two studies were included. Differences in methodology precluded a meta-analysis. The primary outcome, major amputation, was reported in one study, with a rate of 10% in both the intervention and comparison groups (p = 1.00), regardless of treatment duration. For the secondary outcome, remission rates, the first study reported 60% in the intervention group versus 70% in the comparison group (p = 0.50). In the second study, remission rates were 84% in the intervention group versus 78% in the comparison group (p = 0.55). Data for the outcomes mortality, costs, and quality of life were not available. Short treatment duration may lead to fewer adverse events. The risk of bias was assessed as low to moderate, and the level of evidence ranged from very low to moderate. Conclusions: Our findings suggest that for DFO, there is no difference between a shorter and more prolonged duration of antimicrobial treatment regarding amputation and remission, with potentially fewer adverse events with shorter treatment durations. However, the uncertainty stems from limited, heterogeneous studies and generally low-quality evidence marred by moderate biases, imprecision, and indirectness. More high-quality studies are needed to substantiate these findings.

Keywords

antimicrobial therapy, diabetes-related foot osteomyelitis, duration, short versus long, Microbiology, Biochemistry, General Pharmacology, Toxicology and Pharmaceutics, Microbiology (medical), Infectious Diseases, Pharmacology (medical), Journal Article, Review

Citation

Gramberg, M C T T, Torensma, B, van Asten, S, Sieswerda, E, Sabelis, L W E, den Heijer, M, de Vries, R, de Groot, V & Peters, E J G 2024, 'Duration of Antibiotic Treatment for Foot Osteomyelitis in People with Diabetes', Antibiotics, vol. 13, no. 12, 1173. https://doi.org/10.3390/antibiotics13121173